2022
Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021
Chehayeb R, Hood A, Wang X, Miksad R, Mougalian S, Lustberg M, Wang S, Greenup R, Pusztai L, Kunst N. Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021. JAMA Network Open 2022, 5: e2244204. PMID: 36445704, PMCID: PMC9709649, DOI: 10.1001/jamanetworkopen.2022.44204.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerErbB2-positive metastatic breast cancerHR-positive metastatic breast cancerLines of therapyMBC subtypesDrug costsBreast cancerMedical costsHuman epidermal growth factor receptor 2 receptor statusMBC treatmentERBB2-negative metastatic breast cancerAssociated direct medical costsEarly-stage breast cancerHormone receptorsFlatiron Health databaseMetastatic recurrence ratesDifferent drug regimensBreast cancer careData of patientsDirect medical costsNovel adjuvant therapySupportive care drugsOutcomes of interestCost-effectiveness analysisAdjuvant therapy
2020
Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis
Spring L, Fell G, Arfe A, Sharma C, Greenup R, Reynolds K, Smith B, Alexander B, Moy B, Isakoff S, Parmigiani G, Trippa L, Bardia A. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clinical Cancer Research 2020, 26: 2838-2848. PMID: 32046998, PMCID: PMC7299787, DOI: 10.1158/1078-0432.ccr-19-3492.Peer-Reviewed Original ResearchConceptsPathologic complete responseEvent-free survivalBetter event-free survivalNeoadjuvant chemotherapyAdjuvant chemotherapyOverall survivalComplete responseBreast cancerImproved event-free survivalIndividual patient-level dataAdditional adjuvant therapySubsequent adjuvant chemotherapyBreast cancer recurrencePatient-level dataComprehensive Meta-AnalysisAdjuvant settingNeoadjuvant responseAdjuvant therapyMicrometastatic diseaseImproved survivalPrognostic significanceSystemic clearanceCancer recurrenceInclusion criteriaChemotherapy
2017
The Impact of Autologous Breast Reconstruction on Body Mass Index Patterns in Breast Cancer Patients
Cho E, Shammas R, Glener A, Greenup R, Hwang E, Hollenbeck S. The Impact of Autologous Breast Reconstruction on Body Mass Index Patterns in Breast Cancer Patients. Plastic & Reconstructive Surgery 2017, 140: 1121-1131. PMID: 29176410, DOI: 10.1097/prs.0000000000003841.Peer-Reviewed Original ResearchConceptsBody mass index (BMI) changeAutologous breast reconstructionBody mass index increaseBreast cancer patientsBody mass index (BMI) patternsBreast reconstructionCancer patientsMultivariable regressionNormal baseline body mass indexBaseline body mass indexImmediate autologous breast reconstructionCLINICAL QUESTION/LEVELHigh-risk patientsPropensity-matched pairsBody mass indexRisk of recurrenceWeight management strategiesBaseline obesityAdjuvant therapyTotal patientsMass indexTherapeutic mastectomyMastectomy patientsAutologous reconstructionAuthors' institution
2016
A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer
Whitley M, Cardona D, Lazarides A, Spasojevic I, Ferrer J, Cahill J, Lee C, Snuderl M, Blazer D, Hwang E, Greenup R, Mosca P, Mito J, Cuneo K, Larrier N, O'Reilly E, Riedel R, Eward W, Strasfeld D, Fukumura D, Jain R, Lee W, Griffith L, Bawendi M, Kirsch D, Brigman B. A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer. Science Translational Medicine 2016, 8: 320ra4. PMID: 26738797, PMCID: PMC4794335, DOI: 10.1126/scitranslmed.aad0293.Peer-Reviewed Original ResearchConceptsSoft tissue sarcomasLocal recurrenceTumor bedClinical trialsIntravenous injectionPhase 1 clinical trialHuman phase 1 clinical trialCo-clinical studiesMicroscopic residual cancerPositive surgical marginsFuture clinical trialsCo-clinical trialsRates of reexcisionAdjuvant therapyResidual cancerSurgical marginsTreatment failureTissue sarcomasBreast cancerCommon causeIntraoperative detectionMouse modelPharmacokinetic profileSolid tumorsCancer